All In Biotech

Drug Trial Radar · NCT07765914

Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome

Efficacy and Safety of Single-dose Zuberitamab in the Initial Episode of Paediatric Steroid-sensitive Nephrotic Syndrome: A Multicenter Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 20, 2026

Primary completion

Aug 20, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Children's Hospital of Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Guiyang Maternal and Child Health Care Hospital; Wuhan Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Hospital; Wuxi Women's & Children's Hospital; Xiamen Maternity & Child Care Hospital; Second Xiangya Hospital of Central South University
First posted
Aug 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn whether adding Zuberitamab to standard corticosteroid therapy can help prevent relapse in children and adolescents aged 1 to 18 years with newly diagnosed steroid-sensitive nephrotic syndrome (SSNS). It will also learn about the safety of Zuberitamab. The main questions it aims to answer are: * Does Zuberitamab plus standard corticosteroid therapy prolong the time to first relapse compared with standard corticosteroid therapy alone? * What medical problems do participants experience during treatment? Researchers will compare Zuberitamab plus standard corticosteroid therapy to standard corticosteroid therapy alone to see whether adding Zuberitamab improves disease control. Participants will: * Receive standard corticosteroid treatment for approximately 12 weeks, with or without a single intravenous infusion of Zuberitamab after achieving remission * Take preventive antibiotics if they are in the Zuberitamab group * Test their urine daily at home using dipsticks and record results in a diary * Visit the clinic for regular checkups and blood and urine tests during follow-up for up to 12 months

Conditions

  • Nephrotic Syndrome

Interventions

  • ZuberitamabBiological

    Zuberitamab is administered as a single intravenous infusion at a dose of 375 mg/m² (maximum 500 mg) following achievement of steroid-sensitive remission. To reduce the risk of infusion-related reactions, premedication is administered approximately 30 minutes before infusion and may include: * Acetaminophen or ibuprofen; * Cetirizine, cyproheptadine, loratadine, or equivalent antihistamines; * Intravenous methylprednisolone 1.6 mg/kg (maximum 48 mg). Participants receiving zuberitamab also receive prophylactic trimethoprim-sulfamethoxazole (TMP 3 mg/kg every other day; maximum SMZ dose 960 mg every other day) until B-cell recovery. Infusion-related reactions are managed according to protocol-defined procedures, including infusion rate reduction, temporary interruption, permanent discontinuation when clinically indicated, and appropriate supportive therapy.

  • standard corticosteroid treatmentDrug

    standard corticosteroid treatment administered orally to treat steroid-sensitive nephrotic syndrome: 6 weeks at 2 mg/kg (max 60 mg/day), then alternate day steroid 1.5 mg/kg (max 40 mg on alternate days) for 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relapse-free survival time within 12 months after randomizationTime frame: From randomization until first relapse or 12 months after randomization, whichever occurs first.

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Second Xiangya Hospital of Central South University

    Changsha, China

  • Guiyang Maternal and Child Health Care Hospital

    Guiyang, China

  • Shanghai Children's Hospital

    Shanghai, China

  • Shanghai Children's Medical Center

    Shanghai, China

  • Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China

  • Wuhan Children's Hospital

    Wuhan, China

  • Wuxi Women's & Children's Hospital

    Wuxi, China

  • Xiamen Maternity & Child Care Hospital

    Xiamen, China

  • Children's Hospital of Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.